Benzatropine

Structural formula
General
Non-proprietary name	Benzatropine
other names	(3- endo ) -3- (Diphenylmethoxy) -8-methyl-8-azabicyclo [3.2.1] octane
Molecular formula	C 21 H 25 NO
External identifiers / databases
PubChem	1201549
DrugBank	DB00245
Wikidata	Q415026
Drug information
ATC code	N04 AC01
Drug class	Anticholinergic
properties
Molar mass	307.43 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances danger
H and P phrases	H: 301-311-331
	P: 261-280-301 + 310-311
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Benzatropine is a drug from the group of anticholinergics . It is used in the treatment of certain motor movement disorders , such as those that occur in Parkinson's disease or as a side effect of treatment with neuroleptics .

Benzatropine mesilate, the salt of benzatropine and methanesulfonic acid , is used pharmaceutically .

Mechanism of action

Benzatropine is a centrally acting anticholinergic. The combination of the tropine structure of atropine and the benzohydryl structure of diphenhydramine is responsible for the pharmacological effect. Benzatropine blocks the action of acetylcholine and regulates an imbalance between the neurotransmitters acetylcholine and dopamine , which enables its use in the treatment of the symptoms of early Parkinson's disease.

Animal experiments indicate that the anticholinergic effect is about half that of atropine, while the antihistamine effect corresponds to that of pyrilamine . Benzatropine also acts as a functional inhibitor of acid sphingomyelinase ( FIASMA ).

application areas

Benzatropine is indicated for the treatment of:

drug parkinsonoid , akathisia, and acute dystonia
Parkinson's Disease
idiopathic or secondary dystonia

The study situation on the influence of anticholinergics on the occurrence of tardive dyskinesia as an undesirable late consequence of treatment with neuroleptics is inconsistent. Both favorable influence and no influence were found.

Side effects

Basically, side effects are observed with anticholinergics:

Dry mouth
blurred vision
Memory problems
Constipation
Urinary retention
Tachycardia
anorexia
Psychosis (overdose)

Trade names

Cogentin

Individual evidence

↑ ^a ^b Datasheet Benztropine mesylate salt from Sigma-Aldrich , accessed on March 10, 2011 ( PDF ).
↑ External identifiers or database links for benzatropine mesilate: CAS number: 132-17-2, EC number: 205-048-8, ECHA InfoCard: 100.004.591 , ChemSpider : 10481911 , DrugBank : DB00245 , Wikidata : Q27105931 .
↑ MIMS Australia Pty Ltd. MIMS.
↑ Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer T, Spitzer G, Liedl K, Gulbins E, Tripal P: Identification of Novel Functional Inhibitors of Acid Sphingomyelinase . In: PLoS ONE . 6, No. 8, 2011, p. E23852. doi : 10.1371 / journal.pone.0023852 .
↑ John M. Kane: Tardive Dyskinesia. In: Archives of General Psychiatry . 39, 1982, p. 473, doi : 10.1001 / archpsyc.1982.04290040069010 .
↑ Wszola BA, Newell KM, Sprague RL: Risk factors for tardive dyskinesia in a large population of youths and adults . In: Experimental and Clinical Psychopharmacology . 9, No. 3, 2001, pp. 285-296. doi : 10.1037 / 1064-1297.9.3.285 . PMID 11534539 .
^ Van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III . In: The American journal of psychiatry . 155, No. 4, 1998, pp. 565-567. PMID 9546009 .

[Sigma-1] Datasheet Benztropine mesylate salt from Sigma-Aldrich , accessed on March 10, 2011 ( PDF ).

[2] External identifiers or database links for benzatropine mesilate: CAS number: 132-17-2, EC number: 205-048-8, ECHA InfoCard: 100.004.591 , ChemSpider : 10481911 , DrugBank : DB00245 , Wikidata : Q27105931 .

[3] MIMS Australia Pty Ltd. MIMS.

[pmid18504571-4] Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer T, Spitzer G, Liedl K, Gulbins E, Tripal P: Identification of Novel Functional Inhibitors of Acid Sphingomyelinase . In: PLoS ONE . 6, No. 8, 2011, p. E23852. doi : 10.1371 / journal.pone.0023852 .

[5] John M. Kane: Tardive Dyskinesia. In: Archives of General Psychiatry . 39, 1982, p. 473, doi : 10.1001 / archpsyc.1982.04290040069010 .

[pmid11534539-6] Wszola BA, Newell KM, Sprague RL: Risk factors for tardive dyskinesia in a large population of youths and adults . In: Experimental and Clinical Psychopharmacology . 9, No. 3, 2001, pp. 285-296. doi : 10.1037 / 1064-1297.9.3.285 . PMID 11534539 .

[pmid9546009-7] Van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III . In: The American journal of psychiatry . 155, No. 4, 1998, pp. 565-567. PMID 9546009 .